The most recurrent treatment-emergent adverse events observed in LSD1/CoREST-targeting trials include thrombocytopenia, dysgeusia, anemia, gastrointestinal toxicity (diarrhea and constipation), and neutropenia. Here, KDM1A is linked to Thrombocytopenia.